Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that altering auxin storage and conversion pathways in Arabidopsis and maize affects auxin levels and plant development, with implications for overall auxin homeostasis and interactions with gibberellic acid in seed germination.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study found that higher Dietary Inflammatory Index scores were significantly associated with an increase in both the occurrence and severity of alopecia areata.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This abstract reports on the 1997 meeting of the American Society of Hair Restoration Surgeons and the American Academy of Cosmetic Surgery, and it contains no new research findings.

This review discusses the evolution of holding systems in Azerbaijan post-independence, with no new results reported, and highlights the expansion of enterprise consolidation due to economic restructuring and strategic business needs.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This study found that alopecia areata patients had increased insulin resistance compared to controls, suggesting a potential link between inflammation, stress axis activation, and insulin resistance in this population.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study found that RALF peptides, through liquid-liquid phase separation, form condensates with pectin and other proteins, playing a pivotal role in plant development and stress response regulation.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

This study found that while platelet-rich plasma may be effective for alopecia areata, its superiority over intralesional steroid injections was not fully demonstrated, and side effects were more frequent.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This review discusses ischemia-modified albumin as a potential new marker of oxidative stress in dermatological diseases but reports no new clinical findings.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This announcement from the President of the American Board of Hair Restoration Surgery reports the formation and incorporation of the International Board of Hair Restoration Surgery, but offers no new research findings.

This case report highlights significant hair regrowth in a Malaysian woman with localized alopecia areata after intralesional triamcinolone acetonide treatment at a concentration of 5 mg/mL.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

This study demonstrates that an AI-based grading framework using a novel area ratio metric improves the accuracy and consistency of male pattern hair loss classification, especially in advanced grades, compared to traditional methods.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.

This study found that using RADA16-I dressing led to more vigorous hair growth on deep burn wounds compared to other biological materials.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.